 |
Genkyotex
Last updated: July 11, 2025
Elias Papatheodorou, CEO
Switzerland | Funding: $87.1M (+)
Website: http://www.genkyotex.com/
Genkyotex is the leading developer of NOX inhibitors. We are developing first-in-class, small molecule therapeutics that selectively inhibit NOX enzymes. NOX enzymes are key drivers in multiple diseases including fibrotic, inflammatory, cardiovascular and CNS diseases and oncology.
Website: http://www.genkyotex.com/
Genkyotex is the leading developer of NOX inhibitors. We are developing first-in-class, small molecule therapeutics that selectively inhibit NOX enzymes. NOX enzymes are key drivers in multiple diseases including fibrotic, inflammatory, cardiovascular and CNS diseases and oncology.
